United Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. 

CEO
Martine A. Rothblatt
CEOMartine A. Rothblatt
Employees
1,305
Employees1,305
Headquarters
Silver Spring, Maryland
HeadquartersSilver Spring, Maryland
Founded
1996
Founded1996
Employees
1,305
Employees1,305

UTHR Key Statistics

Market cap
17.24B
Market cap17.24B
Price-Earnings ratio
15.28
Price-Earnings ratio15.28
Dividend yield
Dividend yield
Average volume
1.04M
Average volume1.04M
High today
$396.54
High today$396.54
Low today
$375.89
Low today$375.89
Open price
$395.60
Open price$395.60
Volume
892.42K
Volume892.42K
52 Week high
$436.95
52 Week high$436.95
52 Week low
$266.98
52 Week low$266.98

UTHR News

Simply Wall St 1d
United Therapeutics Corporation Surges 38% Yet Its Low P/E Is No Reason For Excitement

United Therapeutics Corporation ( ) shareholders would be excited to see that the share price has had a great month, posting a 38% gain and recovering from prio...

United Therapeutics Corporation Surges 38% Yet Its Low P/E Is No Reason For Excitement
TipRanks 1d
Cautious Optimism for United Therapeutics Amid TETON-2 Success and Market Uncertainties

BTIG analyst Julian Harrison has maintained their neutral stance on UTHR stock, giving a Hold rating yesterday. Elevate Your Investing Strategy: Take advantage...

Benzinga 2d
Why Is United Therapeutics Stock Rallying On Tuesday?

United Therapeutics Corporation UTHR released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution f...

Why Is United Therapeutics Stock Rallying On Tuesday?

Analyst ratings

67%

of 15 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More UTHR News

TipRanks 2d
United Therapeutics Stock Rockets 40% on Clinical Trial Results

United Therapeutics (UTHR) stock rocketed higher on Tuesday after the biotechnology company announced the results of a Phase 3 clinical trial of nebulized Tyvas...

TipRanks 2d
Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint

Markets reopened after the Labor Day break on softer footing, with futures tied to the major indexes pointing lower. Investors are balancing several pressures a...

TipRanks 2d
United Therapeutics Announces Positive TETON-2 Study Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 2d
United Therapeutics announces TETON-2 study meets primary endpoint

United Therapeutics (UTHR) announced that its TETON-2 study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary...

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.